GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indivior PLC (LSE:INDV) » Definitions » Other Gross PPE

Indivior (LSE:INDV) Other Gross PPE : £88.1 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Indivior Other Gross PPE?

Indivior's Other Gross PPE for the quarter that ended in Mar. 2024 was £88.1 Mil.

Indivior's quarterly Other Gross PPE declined from Sep. 2023 (£68.7 Mil) to Dec. 2023 (£0.0 Mil) but then increased from Dec. 2023 (£0.0 Mil) to Mar. 2024 (£88.1 Mil).


Indivior Other Gross PPE Historical Data

The historical data trend for Indivior's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indivior Other Gross PPE Chart

Indivior Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Indivior Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.51 70.49 68.68 - 88.14

Indivior Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Indivior (LSE:INDV) Business Description

Traded in Other Exchanges
Address
234 Bath Road, Slough, Berkshire, GBR, SL1 4EE
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.